THE THERAPEUTIC EFFECT OF CAMPTOTHECIN IN INDUCED ORAL SQUAMOUS CELL CARCINOMA (EXPERIMENTAL STUDY) | ||||
| Alexandria Dental Journal | ||||
| Article 13, Volume 43, Issue 3, December 2018, Page 76-80 PDF (848.41 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/adjalexu.2018.58055 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Hend M. Helmy1; Zeinab E. Darwish2; Sahar M. El-Sheikh2; Marwa M. Afifi3 | ||||
| 1Master in Oral Pathology Department, Faculty of Dentistry, Alexandria University. | ||||
| 2Professor in Oral Pathology Department, Faculty of Dentistry, Alexandria University | ||||
| 3Lecturer in Oral Pathology Department, Faculty of Dentistry, Alexandria University | ||||
| Abstract | ||||
| INTRODUCTION: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, affecting over 400,000 patients, and leading to over 200,000 deaths annually. Camptothecin (CPT), is a potent widely used chemotherapeutic drug. It shows a significant antitumor activity against various types of cancer. It inhibits the activity of DNA topoisomerase I enzyme (TOP I) during the S phase of the cell cycle leading to persisting single-stranded DNA breaks. OBJECTIVES: To study the therapeutic efficacy of CPT chemotherapeutic drug against induced oral squamous cell carcinoma (OSCC). Also the study will evaluate the treatment, by the use of proliferative immune-histochemical marker (PCNA). MATERIALS AND METHODS: Squamous cell carcinoma will be chemically induced in thirty Syrian hamsters. Then they will be divided into two groups, 15 per each. One group will be treated with CPT, The other group will be treated with saline as negative control group. RESULTS: CPT treated animals showed significant results over the control group. CONCLUSIONS: CPT induced apoptosis in tumor cells and enhanced survival rates in comparison to control group < /p> | ||||
| Keywords | ||||
| Oral squamous cell carcinoma; Hamsters; Camptothecin | ||||
| References | ||||
|
1.Ayllon Barbellido S, Campo Trapero J, Cano Sanchez J, Perea Garcia MA, Escudero Castano N, Bascones Martinez A. Gene therapy in the management of oral cancer: review of the literature. Med Oral Patol Oral Cir Bucal. 2008;13:E15-21.
2.Van Monsjou HS, Balm AJ, Van den Brekel MM, Wreesmann VB. Oropharyngeal squamous cell carcinoma: a unique disease on the rise? Oral Oncol. 2010;46:780-5. 3.Vijayakumar M, Burrah R, Sabitha KS, Nadimul H, Rajani BC. To operate or not to operate in the neck in early cancer of the tongue? A prospective study. Indian J Surg Oncol. 2011;2:172-5. 4. Popat K, McQueen K, Feeley TW. The global burden of cancer. Best Pract Res Clin Anaesthesiol. 2013;(4):399-408. 5. Feng L, Eil LL, Soloveiv MM, Wang DS, Zhang BO, Dong YW. Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma. Oncol Lett. 2015;9:1827-32. 6.Hartner L. Chemotherapy for Oral Cancer. Dent Clin North Am. 2018;62:87-97. 7.Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888-90. 8. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA. 2002;99:15387-92. 9. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005;48:2336-45. 10.Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nature Rev. 2006;6:789-802. 11.Palnchon SM, Wuerzberger S, Frydman B, Witiak DT, Huston P, Church DR, et al. â-lapachone mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53 independent respo nse. Cancer Res. 1995;55:3706-11. 12.Ohyama T, Li Y, Utsugi T, Irie S, Yamada Y, Sato T. A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells. Jpn J Cancer Res. 1999;90:691-8. 13.Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle distu rbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer. 1999;35:796-807. 14.World Cancer Report 2014. World Health Organization. 2014. Chapter 5.8. 15.Wu TT, Zhou SH. Nanoparticle-Based Targeted Therapeutics in Head-And-Neck Cancer. Int J Med Sci. 2015;12:187-200. 16.Vairaktaris E, Spyridonidou S, Papakosta V, Vylliotis A, Lazaris A, Perrea D, et al. The hamster model of sequential oral oncogenesis. Oral Oncol. 2008;44:315-24. 17.Taraboletti G, Giavazzi R. Modelling approaches for angiogenesis. Eur J Cancer. 2004;40:881-9. 18.Faccin Bampi V, Ferreira Vilela W, Vilela Gonçalves R, Tavares Rheingantz MG, Minello LF, Braga da Silva JL, et al. The promoting effect of carbamide peroxide teeth bleaching gel in a preclinical model of head and neck cancer in hamster buccal pouch. Clin Exp Otorhinolaryngol. 2014;7:210-5. 19.Sanli UA, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Med Princ Pract. 2006;15:288-92. 20.Rosati G1, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori. 2000;92(4):290-4. 21.Rapic S, Vangestel C, Elvas F, Verhaeghe J, den Wyngaert TV, Wyffels L, et al. Evaluation of [18F]CPT18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology. Mol Imaging Biol. 2017;19:560-9. 22.Qiao L, Pizzolo G, Melamed MR. Effects of selected chemotherapeutic agents on PCNA expression in prostate carcinoma cell lines. Urol Res. 1994;22:171-6. | ||||
|
Statistics Article View: 214 PDF Download: 345 |
||||
